Actively Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Led by Pfizer · Updated on 2026-04-07
310
Participants Needed
28
Research Sites
202 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
CONDITIONS
Official Title
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
- Have measurable disease
- ECOG Performance status of 0 or 1
- Part 1: progression or relapse after standard treatments
- Part 2: no more than 2 prior systemic therapy lines in the advanced setting
- Acute effects of prior anticancer therapies resolved to baseline or Grade 1
- Agree to provide required pre-treatment tumor tissue if medically feasible
You will not qualify if you...
- Prior treatment with an antibody drug conjugate containing a camptothecin-class payload (e.g., sacituzumab govitecan, trastuzumab deruxtecan)
- Active anorexia, nausea, vomiting, or signs of intestinal obstruction as defined by the protocol
- Pulmonary disease meeting protocol exclusion criteria
- Other unacceptable abnormalities as defined by the protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 28 locations
1
City of Hope National Medical Center
Duarte, California, United States, 91010
Actively Recruiting
2
City of Hope at Irvine Lennar
Irvine, California, United States, 92618
Actively Recruiting
3
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States, 90095
Not Yet Recruiting
4
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, California, United States, 90095
Not Yet Recruiting
5
Santa Monica UCLA Medical Center & Orthopaedic Hospital
Santa Monica, California, United States, 90404
Not Yet Recruiting
6
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California, United States, 90404
Not Yet Recruiting
7
Smilow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut, United States, 06510
Actively Recruiting
8
Yale - New Haven Hospital - Yale Cancer Center
New Haven, Connecticut, United States, 06510
Actively Recruiting
9
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut, United States, 06511
Actively Recruiting
10
Smilow Cancer Hospital - Trumbull
Trumbull, Connecticut, United States, 06611
Actively Recruiting
11
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
12
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
13
Dana-Farber Cancer Institute - Chestnut Hill
Newton, Massachusetts, United States, 02467
Actively Recruiting
14
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, United States, 37203
Actively Recruiting
15
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
16
The University of Texas MD Anderson Cancer Center - Conroe
Conroe, Texas, United States, 77384
Not Yet Recruiting
17
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Not Yet Recruiting
18
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas, United States, 77079
Not Yet Recruiting
19
The University of Texas, MD Anderson Cancer Center - League City
League City, Texas, United States, 77573
Not Yet Recruiting
20
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
21
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, Texas, United States, 77478
Not Yet Recruiting
22
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
23
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico, 00935
Actively Recruiting
24
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], Spain, 08035
Actively Recruiting
25
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, Spain, 28041
Actively Recruiting
26
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain, 28040
Actively Recruiting
27
Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London
London, United Kingdom, EC1A 7BE
Not Yet Recruiting
28
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Not Yet Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here